Tejo N. Musunuru, MD

Articles by Tejo N. Musunuru, MD

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.

Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple Myeloma

ByKrina K. Patel, MD,Sairah Ahmed, MD,Tejo N. Musunuru, MD ,Melody R. Becnel, MD

June 20th 2023

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.

Multiple Myeloma: An Evolving Treatment Landscape

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

June 19th 2023

Closing out their discussion on multiple myeloma, expert panelists share expectations and hopes for the future treatment paradigm.

Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

June 12th 2023

Experts in multiple myeloma management review the role of CAR T-cell therapy in patients with relapsed/refractory disease.

Bispecifics in Relapsed/Refractory Multiple Myeloma: Adverse Event Management

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

June 12th 2023

Focused discussion on mitigating and managing the adverse event profiles of bispecifics in relapsed/refractory multiple myeloma.

Dosing and Sequencing Bispecifics and CAR T-Cell Therapies in R/R MM

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

June 5th 2023

Key opinion leaders share comprehensive insight on optimal dosing and sequencing strategies in patients with relapsed/refractory multiple myeloma.

RRMM: Access to Bispecifics and CAR T-Cell Therapy in Satellite Campuses

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

June 5th 2023

A brief conversation on the introduction and use of bispecifics and CAR T-cell therapies in satellite campuses for patients with relapsed/refractory multiple myeloma.

Expanding the Treatment Armamentarium in RRMM with Novel Therapies

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 29th 2023

Switching focus to the relapsed/refractory setting, panelists reflect on the treatment armamentarium available to patients with multiple myeloma at early relapse.

Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 29th 2023

Key opinion leaders in multiple myeloma consider duration of therapy and the possibility of treatment discontinuation for newly diagnosed patients.

Treatment Paradigm for Patients With Transplant Ineligible NDMM

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 22nd 2023

Centering discussion on transplant ineligible multiple myeloma, expert panelists review mainstay treatment regimens and strategies in the first-line setting.

Treatment of MM: Value of Tumor Boards in Practice

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 22nd 2023

Shared insight on the respective value of consolidation therapy and collaborative tumor boards when managing patients with transplant-eligible multiple myeloma.

Role of Transplant in Newly Diagnosed Multiple Myeloma

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 15th 2023

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma

ByKrina K. Patel, MD,Sairah Ahmed, MD,Melody R. Becnel, MD ,Tejo N. Musunuru, MD

May 15th 2023

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.